RecruitingNCT07203768
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Principal Investigator
- TIZIANO BARBUI, MDFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Enrollment
- 678 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2025 – 2026
Study locations (25)
- Mayo Clinic, Rochester, Minnesota, United States
- University Hospital Halle, Halle, Germany
- Hannover Medical School, Hanover, Germany
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center, Minden, Germany
- Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardy, Italy
- Divisione Ematologia, Ospedale San Bortolo, Vicenza, Veneto, Italy
- A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia, Alessandria, Italy
- ASST Papa Giovanni XXIII, SC Ematologia, Bergamo, Italy
- ASST-Spedali Civili, Brescia, Italy
- Ospedale Businco, Cagliari, Italy
- AOU Policlinico Vittorio Emanuele - PO Gaspare Rodolico, Catania, Italy
- AOU Careggi, Divisione di Ematologia, Florence, Italy
- ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia, Milan, Italy
- Fondazione IRCCS Cà Grande - Op. Maggiore Policlinico, Milan, Italy
- Ospedale San Raffaele, Milan, Italy
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07203768 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06327100Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)M.D. Anderson Cancer Center